ClinicalTrials.gg
CompletedNCT06088199Updated Oct 23, 2026

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

A Phase 3 interventional study of Apremilast in Plaque Psoriasis, sponsored by Amgen. Completed at 30 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.

Enrollment
28th of 44
51 · median 103
Started
2023
with 3 others
Phase 3
18 of 44
none open now
Registered
39th of 44
by date
Lead sponsor
25 of 44
Amgen

Among the 44 studies testing apremilast in Psoriasis, this one is the 28th largest by enrollment, is one of 4 that started in 2023, is one of 18 in phase 3, and was the 39th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing apremilast in Psoriasis, or all of them as a file.
02

Study summary

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Apremilast
  • Otezla
  • AMG 407
  • CC-10004
  • Pediatric
  • Plaque psoriasis
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a weight of ≥ 20 kg.
  • Participant must have an age and sex specific value no lower in range than the fifth percentile on the growth chart for children and adolescents.
  • Participant is able to swallow the study medication tablet.
  • Diagnosis of chronic plaque psoriasis for at least 6 months prior to screening.
  • Has mild to moderate plaque psoriasis at screening and Study Visit 1 as defined by:
  • Psoriasis Area Severity Index score 2-15,
  • Body surface area 2-15%, and
  • Static Physician Global Assessment score of 2-3 (mild to moderate)
  • Disease inadequately controlled by or inappropriate for topical therapy for psoriasis.

Exclusion criteria

Exclusion Criteria:

  • Guttate, erythrodermic, or pustular psoriasis at screening and Study Day 1.
  • Psoriasis flare or rebound within 4 weeks prior to screening.
  • Active tuberculosis (TB) or a history of incompletely treated TB per local guidelines.
  • History of recurrent significant infections.
  • Active infection or infection treated with antibiotic treatment within 14 days of Study Day 1.
  • Any history of or active or myeloproliferative or lymphoproliferative disease.
  • Current use of the following therapies that may have a possible effect on psoriasis:
  • Conventional systemic therapy for psoriasis within 28 days prior to Study Day 1 (including but not limited to cyclosporine, , methotrexate, oral retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, and fumaric acid esters).
  • Phototherapy treatment (ie, ultraviolet B [UVB], PUVA) within 28 days prior to Study Day 1.
  • Biologic therapy:

    • Etanercept (or biosimilar) treatment 28 days prior to Study Day 1
    • Adalimumab (or biosimilar) treatment 10 weeks prior to Study Day 1
    • Other TNF or IL-17 blockers (such as infliximab, certolizumab pegol, secukinumab, ixekizumab, brodalumab, or their biosimilars) within 12 weeks prior to Study Day 1
    • Anti-IL-12 or anti-IL-23 treatment (such as ustekinumab, guselkumab, or tildrakizumab) within 24 weeks prior to Study Day 1.
  • Use of tanning booths or other ultraviolet light sources.
  • Answer "Yes" to any question on the Columbia-Suicide Severity Rating Scale during screening or at Study Day 1.
  • Female participant of with a positive pregnancy test assessed at screening and/or Study Day 1 by a serum and/or urine pregnancy test.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Apremilast

    Apremilast will be dosed by participant's body weight and administered twice daily (BID) in the form of oral tablets, approximately 12 hours apart, without restriction of food or drink.

    Drug: Apremilast

Interventions

  • Oral tablet

    Also known as: AMG 407, Otezla, CC-10004

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events

    Time frame: Day 1 up to approximately 285 days

Secondary outcomes

  1. Growth and Development as Assessed by Height

    Time frame: Day 1 up to approximately 285 days

  2. Growth and Development as Assessed by Weight

    Time frame: Day 1 up to approximately 285 days

  3. Growth and Development as Assessed by Body Mass Index (BMI)

    Time frame: Day 1 up to approximately 285 days

  4. Columbia-Suicide Severity rating Scale (C-SSRS)

    Time frame: Day 1 to Day 225

  5. Tanner Staging of Sexual Maturity

    Time frame: Day 1 and Day 225

  6. Number of Participants With Psoriasis Flare

    Time frame: Up to approximately 285 days

  7. Number of Participants With Psoriasis Rebound

    Time frame: Up to approximately 285 days

  8. Number of Participants Experiencing Diarrhea Sympotms as Assessed by Stool Diaries

    Time frame: Day 1 to Day 225

  9. Number of Participants with Clinically Significant Changes in Laboratory Parameters

    Time frame: Up to approximately 225 days

  10. Number of Participants with Clinically Significant Changes in Vital Signs

    Time frame: Up to approximately 285 days

07

Study locations

30 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Affiliated Dermatology
    Scottsdale, Arizona 85255, United States
  • Clear Dermatology
    Scottsdale, Arizona 85255, United States
  • Johnson Dermatology Clinic
    Fort Smith, Arkansas 72916, United States
  • Avance Clinical Trials
    Laguna Niguel, California 92677, United States
  • University of California Irvine
    Orange, California 92868, United States
  • MedDerm Associates
    San Diego, California 92103, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • California Dermatology Institute
    Thousand Oaks, California 91320, United States
  • Pediatric Skin Research LLC
    Coral Gables, Florida 33146, United States
  • Ciocca Dermatology
    Miami, Florida 33173, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Endeavor Health Clinical Trials Center
    Skokie, Illinois 60077, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • Southern Indiana Clinical Trials
    New Albany, Indiana 47150, United States
  • Great Lakes Research Group Inc- Sheffield
    Bay City, Michigan 48706, United States
  • Henry Ford Medical Center - New Center One
    Detroit, Michigan 48202, United States
  • Dermatology and Skin Cancer Center of Lees Summit
    Lee's Summit, Missouri 64064, United States
  • Boeson Research
    Missoula, Montana 59804, United States
  • Empire Dermatology
    East Syracuse, New York 13057, United States
  • State University of New York, Downstate Medical Center
    Manhasset, New York 11030, United States
  • OptiSkin Medical
    New York, New York 10029, United States
  • Hightower Clinical LLC
    Oklahoma City, Oklahoma 73120, United States
  • Dermatology Research Center of Oklahoma, PLLC
    Tulsa, Oklahoma 74132, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Studies in Dermatology LLC
    Cypress, Texas 77429, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
  • Stride Clinical Research LLC
    Sugar Land, Texas 77479, United States
  • Frontier Derm Partners
    Mill Creek, Washington 98012, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Aug 2026, 33 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 33 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2023
First posted
Oct 18, 2023
StartActual
Oct 24, 2023
Primary completionActual
Aug 12, 2026
CompletionActual
Aug 12, 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06088199
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 18, 2023
Start date
Oct 24, 2023
Primary completion
Aug 12, 2026
Completion
Aug 12, 2026
Last update
Oct 23, 2026

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion